Successful ceftolozane-tazobactam rescue therapy in a child with endocarditis caused by multidrug-resistant Pseudomonas aeruginosa
Successful ceftolozane-tazobactam rescue therapy in a child with endocarditis caused by multidrug-resistant Pseudomonas aeruginosa
复制标题
DOI：
10.1111/jpc.14388
复制
发表时间：
2019-08-01
影响因子：
1.7
通讯作者：
Blazquez-Gamero, Daniel
中科院分区：
文献类型：
--
作者：
Martin-Cazana, Maria;Grau, Santiago;Blazquez-Gamero, Daniel
头孢洛扎-他唑巴坦可作为对该抗生素敏感的多重耐药铜绿假单胞菌引起的心内膜炎儿童的替代治疗选择。入院第8天，患者发生进行性管道狭窄、右心室衰竭、血培养中铜绿假单胞菌i持续存在，尽管接受抗生素治疗，但临床无改善。儿童多重耐药（MDR）铜绿假单胞菌i，尤其是碳青霉烯类耐药铜绿假单胞菌i的抗生素治疗选择很少。i头孢洛扎-他唑巴坦是最近批准用于治疗成人复杂性腹腔内和尿路感染的一种新抗生素。[摘自文章]
Ceftolozane-tazobactam can be an alternative treatment option for children with endocarditis caused by multidrug-resistant I Pseudomonas aeruginosa i sensitive to this antibiotic. On the eighth day of admission, the patient developed progressive conduit stenosis, right ventricle failure, persistence of I P. aeruginosa i in blood cultures and absence of clinical improvement despite antibiotic therapy. There are few options of antibiotic treatment in children with multidrug-resistant (MDR) I P. aeruginosa i, especially in carbapenem-resistant I P. aeruginosa. i Ceftolozane-tazobactam is a new antibiotic recently approved for the treatment of complicated intra-abdominal and urinary tract infections in adults.[Extracted from the article]